NCT06879834 Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
| NCT ID | NCT06879834 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Filatov Institute of Eye Diseases and Tissue Therapy |
| Condition | Diabetic Retinopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-02 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-02 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.
Eligibility Criteria
Inclusion Criteria: 1. Documented diagnosis of diabetes mellitus by definition. 2. Understanding of the Study and willingness and ability to sign informed consent 3. Patient age 18 or above 4. Diagnostic for diabetes: 4a) Type 1 diabetes of a lest 5 years of evolution; or 4b) Type 2 diabetes Exclusion Criteria: -1. Patients under 18 years of age; 2. Failure to give informed consent; 3. Presence of retinal diseases - acquired disease: age-related macular degeneration (AMD), occlusion of retinal vessels (ORV), etc.; birth defects: coloboma of choroid or optic nerve disc, etc.; hereditary diseases: retinitis pigmentosa, angioid streaks of the retina, etc. 4\. A patient who has already undergone treatment (surgery, laser, etc.) for any disease of the retina: age-related macular degeneration (AMD), retinal vascular occlusion (ARV), etc. These patients should be excluded or allocated to a separate group.
Contact & Investigator
Andrii MD Korol, PhD
PRINCIPAL INVESTIGATOR
The Filatov Institute of Eye Diseases and Tissue Therapy
Frequently Asked Questions
Who can join the NCT06879834 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06879834 currently recruiting?
Yes, NCT06879834 is actively recruiting participants. Contact the research team at andrii.r.korol@gmail.com for enrollment information.
Where is the NCT06879834 trial being conducted?
This trial is being conducted at Odesa, Ukraine.
Who is sponsoring the NCT06879834 clinical trial?
NCT06879834 is sponsored by The Filatov Institute of Eye Diseases and Tissue Therapy. The principal investigator is Andrii MD Korol, PhD at The Filatov Institute of Eye Diseases and Tissue Therapy. The trial plans to enroll 200 participants.